Logo Image
News|Podcasts|September 23, 2026

The BioPharm Brief: Earlier Treatment, New Testing, and Sjögren’s Data

FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here’s what we have today.

First, FDA has expanded the US label for Merck’s Winrevair. The update adds data from the Phase 3 HYPERION trial in adults diagnosed with pulmonary arterial hypertension within the previous 12 months. Adding Winrevair to background therapy reduced the risk of clinical worsening events by 76% compared with placebo, supporting its use earlier in the treatment course.

FDA is also formally recognizing non-animal testing methods. A new direct final rule updates regulatory language to clarify that methods such as human cells, organoids, organs-on-chips, and computer models can be used when appropriate to generate nonclinical safety information. The rule does not eliminate animal studies, and developers still need to demonstrate that an alternative method is fit for purpose.

And Amgen’s dazodalibep has hit its Phase 3 primary endpoint in Sjögren disease. The OASIZ 301 trial showed statistically significant and clinically meaningful improvement in systemic disease activity at week 48, with improvements seen as early as week 4. Dazodalibep is a CD40 ligand antagonist, and Amgen says a second Phase 3 trial is expected to read out in the fourth quarter.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • FDA expands Winrevair’s label for patients with recently diagnosed pulmonary arterial hypertension.
  • FDA formalizes non-animal testing methods, including emerging approaches such as organoids and organs-on-chips.
  • Amgen’s dazodalibep hits its Phase 3 endpoint in Sjögren disease, advancing a potential new treatment option.

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more